Cogent Biosciences, Inc.
COGT • NASDAQ
Cogent Biosciences, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Andrew R. Robbins, with a market cap of $5.9B.
CEOAndrew R. Robbins
Next Earnings
Upcoming earnings announcement for Cogent Biosciences, Inc.
Date
Tuesday, May 5, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.54
Earnings History
Past 12 earnings reports for Cogent Biosciences, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | Q4 2025 | -$0.61Est: -$0.51 | -19.6% | - | — |  10-K |
| Nov 3, 2025 | Q3 2025 | -$0.50Est: -$0.52 | +3.8% | - | — | 10-Q |
| Aug 5, 2025 | Q2 2025 | -$0.53Est: -$0.57 | +7.0% | - | — | 10-Q |
| May 6, 2025 | Q1 2025 | -$0.52Est: -$0.58 | +10.3% | - | — | 10-Q |
| Feb 25, 2025 | Q4 2024 | -$0.09Est: -$0.58 | +84.5% | - | — | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.64Est: -$0.57 | -12.3% | - | — | 10-Q |
| Aug 6, 2024 | Q2 2024 | -$0.59Est: -$0.56 | -5.4% | - | — | 10-Q |
| May 7, 2024 | Q1 2024 | -$0.62Est: -$0.51 | -21.6% | - | — | 10-Q |
| Feb 26, 2024 | Q4 2023 | -$0.63Est: -$0.55 | -14.5% | -Est: - | — | 10-K |
| Nov 2, 2023 | Q3 2023 | -$0.64Est: -$0.50 | -28.0% | - | — | — |
| Aug 8, 2023 | Q2 2023 | -$0.59Est: -$0.55 | -7.3% | - | — | 10-Q |
| May 9, 2023 | Q1 2023 | -$0.54Est: -$0.57 | +5.3% | - | — | — |